Linsitinib (OSI-906)

製品コードS1091

Linsitinib (OSI-906)化学構造

分子量(MW):421.49

Linsitinib (OSI-906)は一種の選択性的なIGF-1R阻害剤で、無細胞実験で、IC50値が35 nMです。OSI-906 (Linsitinib)はInsRを適合に抑制して、このIC50値が75 nMになリますが、Abl、ALK、BTK、EGFR、FGFR1/2とPKA等に抑制活性を表しません。臨床3期。

サイズ 価格 在庫  
USD 239 あり
USD 214 あり
USD 340 あり
USD 907 あり

カスタマーフィードバック(4)

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

製品安全説明書

IGF-1R阻害剤の選択性比較

生物活性

製品説明 Linsitinib (OSI-906)は一種の選択性的なIGF-1R阻害剤で、無細胞実験で、IC50値が35 nMです。OSI-906 (Linsitinib)はInsRを適合に抑制して、このIC50値が75 nMになリますが、Abl、ALK、BTK、EGFR、FGFR1/2とPKA等に抑制活性を表しません。臨床3期。
ターゲット
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)
ALK [1]
(Cell-free assay)
35 nM 75 nM 75 nM >10 μM >10 μM
体外試験

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M3PFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK1eIY4UUN3ME2wMlAzQDB4IN88US=> NWP1PFFCW0GQR1XS
KS-1 NIPaUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O0NWlEPTB;MD6wN|g{PSEQvF2= MnjoV2FPT0WU
TE-11 NIPLWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu4fnZKSzVyPUCuNFc5OjJizszN NHP6eYxUSU6JRWK=
EW-1 M4P5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEi1PFUh|ryP NGW3b|BUSU6JRWK=
HMV-II MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[xTWM2OD1yLkC4PFQ3KM7:TR?= MV\TRW5ITVJ?
COLO-205 M2T4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vOTmlEPTB;MD6xNFQ2PCEQvF2= NWfmS3ZiW0GQR1XS
ES1 MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MliyTWM2OD1yLkGwOlk3KM7:TR?= NYTacnhXW0GQR1XS
GDM-1 M2rrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnpNlBKSzVyPUCuNVM3PzJizszN MkfOV2FPT0WU
ML-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMUW4PVYh|ryP NGWxRXRUSU6JRWK=
Saos-2 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKyTWM2OD1yLkG2OVI3KM7:TR?= MV7TRW5ITVJ?
NCI-H1355 M3fIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTrTWM2OD1yLkG4NVM2KM7:TR?= MnLmV2FPT0WU
G-401 NXzsc5pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMUiyN{DPxE1? MnzYV2FPT0WU
EW-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMUi3O|ch|ryP NUC2PGZNW0GQR1XS
EW-7 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz1SJpJUUN3ME2wMlE5QDhzIN88US=> Mn;NV2FPT0WU
NCI-H727 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rn[WlEPTB;MD6xPVc6PCEQvF2= NV3iWZJ3W0GQR1XS
LCLC-97TM1 MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DuWWlEPTB;MD6yNFk2PSEQvF2= MWTTRW5ITVJ?
NCI-H650 NVLFeHhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\qTWM2OD1yLkKxN|g1KM7:TR?= M3P0XHNCVkeHUh?=
NCI-H2122 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTabpRqUUN3ME2wMlI{Ojl7IN88US=> MWrTRW5ITVJ?
SK-N-DZ NUi4dJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMkO2PVgh|ryP NIfOdJhUSU6JRWK=
HT-29 M4P3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zTSmlEPTB;MD6yOFI1QCEQvF2= MXLTRW5ITVJ?
LB771-HNC Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjqWlBKSzVyPUCuNlU6OTVizszN NFL2d|JUSU6JRWK=
HT-144 NWfMVHR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMk[xPVEh|ryP MV7TRW5ITVJ?
LAN-6 NYPLSIJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMk[zOFgh|ryP NVP5TWxFW0GQR1XS
EW-18 NYX4PVNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPwepJKSzVyPUCuNlcxODFizszN NGfycYxUSU6JRWK=
LS-1034 NX\2TVc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\ITWM2OD1yLkK3NVMzKM7:TR?= NF33PFBUSU6JRWK=
EW-11 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMki0N|Ih|ryP NUXBfGN7W0GQR1XS
SNU-C1 NVPzO2lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMkmzNVMh|ryP NFPKbIpUSU6JRWK=
RS4-11 NWPUUnE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXUTWM2OD1yLkOzO|U5KM7:TR?= Mnz5V2FPT0WU
ES4 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3La[GlEPTB;MD60NVA{QCEQvF2= NULvfFNUW0GQR1XS
COLO-320-HSR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwNEGzOlgh|ryP NHXJOZNUSU6JRWK=
NB10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfTO3ZNUUN3ME2wMlQ2PDN5IN88US=> M{j3b3NCVkeHUh?=
BFTC-905 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDsTWM2OD1yLkS2O|U5KM7:TR?= M2m3XHNCVkeHUh?=
A375 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jkOGlEPTB;MD60O|YyPyEQvF2= NFixZmdUSU6JRWK=
SJRH30 M3fZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zvV2lEPTB;MD61NFgzOiEQvF2= NXHxR3JzW0GQR1XS
NOS-1 NILLVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwNUKyOlch|ryP NEf2XZZUSU6JRWK=
SIG-M5 NVLnV29oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojWTWM2OD1yLkWzOVU4KM7:TR?= NYHkdItRW0GQR1XS
DOK M1vmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwNUW2JO69VQ>? NYrKSpBIW0GQR1XS
NB69 NYXBUFkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTpeY1zUUN3ME2wMlU5OjV5IN88US=> NHTZVotUSU6JRWK=
SK-NEP-1 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwNkCyN|Yh|ryP NEfobI9USU6JRWK=
SK-MM-2 NICxU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLpd2NKSzVyPUCuOlU1QTFizszN Ml;0V2FPT0WU
NCI-H358 M3ToN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHnephsUUN3ME2wMlY4ODh{IN88US=> NX;NToduW0GQR1XS
RH-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe5[IlRUUN3ME2wMlc1QDV7IN88US=> NIL0OnJUSU6JRWK=
NH-12 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\TTWM2OD1yLke2NFQ3KM7:TR?= M{jKNnNCVkeHUh?=
TE-12 NGLTT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETHbHpKSzVyPUCuO|Y1QDZizszN M1PoPXNCVkeHUh?=
COLO-668 M2DpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXDNYJKSzVyPUCuPFQ3PjZizszN M3\3PHNCVkeHUh?=
PANC-08-13 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TzU2lEPTB;MD64OlM4PyEQvF2= MYDTRW5ITVJ?
HCC2998 NGewOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDqdmZiUUN3ME2wMlg5OjZ|IN88US=> MXPTRW5ITVJ?
ABC-1 NHXSRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfDTWM2OD1yLkmwN|UzKM7:TR?= NH;UNJlUSU6JRWK=
ES6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\DZmZKSzVyPUCuPVExPjZizszN NXHEb3R6W0GQR1XS
SNU-387 M{HqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvTTWM2OD1yLkm5N|k{KM7:TR?= MVXTRW5ITVJ?
CMK NWTXOGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPC[GJvUUN3ME2wMlk6QTJ7IN88US=> M4TKPHNCVkeHUh?=
SJSA-1 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f2d2lEPTB;MT6wN|Y2OyEQvF2= MmrCV2FPT0WU
SIMA MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nQVGlEPTB;MT6wOlgzPSEQvF2= Mlq2V2FPT0WU
ES3 NUDib3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzUeGtKSzVyPUGuNVIzQTdizszN NGizbFRUSU6JRWK=
IGROV-1 MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnDVY9vUUN3ME2xMlE2PDR2IN88US=> M2\0SnNCVkeHUh?=
MEL-JUSO NWL4RoNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHDTHBKSzVyPUGuNVU4PTlizszN MVnTRW5ITVJ?
T84 M1;D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;6c2w6UUN3ME2xMlIxQTF2IN88US=> MlG1V2FPT0WU
CAL-85-1 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvLTWM2OD1zLkKzNVM5KM7:TR?= MmP1V2FPT0WU
RD NYHmO3Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwMk[0OVUh|ryP NXLCTG5pW0GQR1XS
TE-8 NV\CZ25QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjEc|JKSzVyPUGuN|E1PjJizszN M3zrW3NCVkeHUh?=
L-363 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH4TWM2OD1zLkO0NlA5KM7:TR?= NUPzT|kyW0GQR1XS
EKVX NHe5WJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTifnNQUUN3ME2xMlM1PTZ6IN88US=> MWrTRW5ITVJ?
SK-MEL-3 NV71T|djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPjTWM2OD1zLkS4OVU3KM7:TR?= NWrnb3FtW0GQR1XS
TGBC24TKB NXzFO3lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7OWlI5UUN3ME2xMlUxOTl|IN88US=> NIi1R3BUSU6JRWK=
NCI-H1770 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fURmlEPTB;MT61NVEyOyEQvF2= M16xfXNCVkeHUh?=
HuH-7 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\JTJNjUUN3ME2xMlYxODl6IN88US=> MlzmV2FPT0WU
HL-60 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPjTWM2OD1zLk[2PVI5KM7:TR?= Mn;lV2FPT0WU
TE-1 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDQTWM2OD1zLkewPVQ2KM7:TR?= NG\lSmFUSU6JRWK=
LC-2-ad M1TjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XlVWlEPTB;MT63N|g5PyEQvF2= NU\VOnc6W0GQR1XS
LB647-SCLC NYm3clRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X4VGlEPTB;MT63OlU5OyEQvF2= M3nmWHNCVkeHUh?=
NCI-H2171 NY[1[nozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zkemlEPTB;MT63O|cyPiEQvF2= MojDV2FPT0WU
SK-PN-DW NXz0Ro1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwOUGyPVgh|ryP NYfuXGNiW0GQR1XS
MC-IXC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFwOUi5PEDPxE1? NV3rbXQ4W0GQR1XS
LS-513 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJwMEWzNFUh|ryP NFrqUnFUSU6JRWK=
EW-3 NGHpTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjYdpZKSzVyPUKuNFk5PDRizszN MmO4V2FPT0WU
OPM-2 NHnk[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\DbmlEPTB;Mj6xNFIh|ryP MXzTRW5ITVJ?
LP-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq3S4VKSzVyPUKuNlU5ODdizszN NWHJTXF7W0GQR1XS
LU-134-A M4XNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP2XlBKSzVyPUKuNlc4KM7:TR?= M4XOUXNCVkeHUh?=
CP66-MEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICwOFJKSzVyPUKuNlkxOTRizszN NY\4blltW0GQR1XS
HCC1143 NXLRUHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3pdIo1UUN3ME2yMlQ2OzZ6IN88US=> MnLxV2FPT0WU
LOXIMVI M1XmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwNkCyNUDPxE1? Mo\jV2FPT0WU
TE-10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwN{C4N|gh|ryP M{PZUnNCVkeHUh?=
NCI-H1882 NGDQW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXNUGZ2UUN3ME2yMlc2OjJ5IN88US=> NVzYbJlYW0GQR1XS
CHP-126 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkToTWM2OD1{Lke2N|E4KM7:TR?= NWPzV5ZnW0GQR1XS
NCI-H1623 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwOUKwNlQh|ryP M1LTfHNCVkeHUh?=
GB-1 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPKfJF2UUN3ME2yMlk{PDB2IN88US=> MV7TRW5ITVJ?
RCC10RGB M3e1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fNc2lEPTB;Mj65OVI5OSEQvF2= NFqwbmJUSU6JRWK=
NCI-H2141 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPYO5FxUUN3ME2yMlk3QDl4IN88US=> M3jOOHNCVkeHUh?=
GI-ME-N M4[2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHnb4FKSzVyPUOuNFA2PjVizszN M1XqUHNCVkeHUh?=
NCI-H526 NYPRTJJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfCTWM2OD1|LkC0NFg2KM7:TR?= NUG4fmc3W0GQR1XS
NCI-H747 NUHlNFJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNwMES5PVIh|ryP MmjJV2FPT0WU
SNU-423 M4C0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNwMkCzNVMh|ryP NGDPeGtUSU6JRWK=
A427 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL5dWVKSzVyPUOuNlU3QTlizszN MXnTRW5ITVJ?
CAL-12T MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv0T4RwUUN3ME2zMlQxPzF|IN88US=> NEi5eVBUSU6JRWK=
LU-99A MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3HSFVkUUN3ME2zMlQ4OTB3IN88US=> MmLzV2FPT0WU
MS-1 M1PXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HYfWlEPTB;Mz61N|QzQSEQvF2= M3z2T3NCVkeHUh?=
SK-LU-1 NGXmS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\WTWM2OD1|Lke2Nlk2KM7:TR?= MYjTRW5ITVJ?
SW837 NIj4[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjvTWM2OD1|Lke2N|M{KM7:TR?= MofxV2FPT0WU
ES8 M4DrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjFS3FKSzVyPUOuPFM5PzdizszN MW\TRW5ITVJ?
MZ2-MEL NV7HXnNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTJfJFKSzVyPUOuPVIxQDZizszN MVvTRW5ITVJ?
TGW NELV[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2np[GlEPTB;ND6wNVMyOSEQvF2= M1zRRXNCVkeHUh?=
GP5d NWrydoVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHHO41KSzVyPUSuNFU{PjJizszN NGfjVmlUSU6JRWK=
BB49-HNC M{PmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonUTWM2OD12LkG1NlE{KM7:TR?= NFHqcolUSU6JRWK=
NB13 NGfkN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn5PZFvUUN3ME20MlI3QDh5IN88US=> Ml3jV2FPT0WU
NTERA-S-cl-D1 NF3aWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPwTWM2OD12LkK4OlE2KM7:TR?= MlvzV2FPT0WU
NCI-H1648 NULmcJJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRwMkm4NVkh|ryP M4i3c3NCVkeHUh?=
LCLC-103H MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n2RmlEPTB;ND6zNlE6PSEQvF2= NUfn[WpXW0GQR1XS
LS-411N MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvxV4FKSzVyPUSuOFQ5QDVizszN M{jMRXNCVkeHUh?=
NCI-H1092 M2jLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDCWIhKSzVyPUSuOFU3QDdizszN NGq2cmtUSU6JRWK=
PANC-10-05 NE[ye|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoflTWM2OD12Lk[5PFQh|ryP M{\RcXNCVkeHUh?=
DK-MG NF7LUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\HN5ZKSzVyPUSuPFA6OzNizszN MYnTRW5ITVJ?
OVCAR-5 NHWwVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHpUo1EUUN3ME20MlgyOjJ4IN88US=> NVruO4MxW0GQR1XS
CAL-39 NEHhWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF24ZVlKSzVyPUSuPFc3PyEQvF2= MnzJV2FPT0WU
TE-441-T M13pSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRwOUC1N|ch|ryP NV3TZZI6W0GQR1XS
MOLT-16 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwOUWyOVMh|ryP M{n2ZXNCVkeHUh?=
MCF7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW4XFdCUUN3ME21MlE1PTF5IN88US=> MYTTRW5ITVJ?
CAPAN-1 M2W4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTVwMkW3NFch|ryP MX3TRW5ITVJ?
PSN1 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S3e2lEPTB;NT6yO|I{PSEQvF2= NGPHOJdUSU6JRWK=
NCI-H292 M2T2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTVwM{CwOFQh|ryP MlvZV2FPT0WU
CPC-N M4fYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DDdGlEPTB;NT6zPVQyQSEQvF2= NW\CVldGW0GQR1XS
DoTc2-4510 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTVwNEWzO|Eh|ryP MX\TRW5ITVJ?
LB1047-RCC MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[zb2lEPTB;NT61OVk{OyEQvF2= M{ftXHNCVkeHUh?=
MHH-ES-1 M1X2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTVwNUm5NFch|ryP NGDpZVNUSU6JRWK=
NMC-G1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDBSmtWUUN3ME21MlcxOjJ5IN88US=> NV3CXWt1W0GQR1XS
SW1710 NEn2OW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfMdFlKSzVyPUWuO|Q4PTFizszN NITUPWpUSU6JRWK=
YAPC NGnXO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\TbJVZUUN3ME21Mlc3OjBzIN88US=> NG\TZZVUSU6JRWK=
22RV1 M2rDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HVd2lEPTB;NT64NFAyQSEQvF2= MljtV2FPT0WU
COLO-679 M2fUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofoTWM2OD13Lki4PVQ5KM7:TR?= MlnPV2FPT0WU
TCCSUP NHPWNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zCcWlEPTB;NT65N|I2QSEQvF2= MmrMV2FPT0WU
C2BBe1 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTMTWM2OD13LkmzPVch|ryP M3TOU3NCVkeHUh?=
TE-15 NYfk[ndwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXwSW5vUUN3ME22MlA3PjB3IN88US=> M1H5NnNCVkeHUh?=
SCLC-21H MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmyTWM2OD14LkGwPFQ{KM7:TR?= MVnTRW5ITVJ?
EoL-1-cell M2TWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnOdXA1UUN3ME22MlE3PTZ|IN88US=> MmfhV2FPT0WU
NKM-1 NHHHT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXwPJhxUUN3ME22MlE3PzFizszN NHPlR2NUSU6JRWK=
NCI-H1304 M1m5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTZwMke0Nlgh|ryP MXvTRW5ITVJ?
NB6 NWTVU49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTZwMkm2NlIh|ryP NIrOUGlUSU6JRWK=
NALM-6 M1\SeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;heIVKSzVyPU[uN|MzOyEQvF2= NV3iTpd7W0GQR1XS
NCI-H522 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTZwM{OzNFYh|ryP MULTRW5ITVJ?
MV-4-11 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;5TWM2OD14LkO3NFc6KM7:TR?= NUnwN2l7W0GQR1XS
LB2241-RCC M2C3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPNUJlmUUN3ME22MlM5PjZ5IN88US=> NFPPUotUSU6JRWK=
NCI-H1417 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy2[WF{UUN3ME22MlQxQDR5IN88US=> Mn\IV2FPT0WU
HT-1197 NIXveWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTZwNUexNlIh|ryP MmjsV2FPT0WU
P30-OHK NGjKfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X5[GlEPTB;Nj62Nlc4KM7:TR?= NVe4XWpLW0GQR1XS
ALL-PO Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LQO2lEPTB;Nj63NVkyPiEQvF2= NUDwe2dPW0GQR1XS
OVCAR-4 NIXtemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\3VVAyUUN3ME22Mlc2PDB3IN88US=> NWHyeJdqW0GQR1XS
HCC2157 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j2OWlEPTB;Nj63O|Q4PSEQvF2= M2LGNXNCVkeHUh?=
NCI-H838 M4T0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrxR2VKSzVyPU[uPVY1QSEQvF2= NFfNU3NUSU6JRWK=
NCI-H1299 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrSW3lKSzVyPU[uPVcxQSEQvF2= MYrTRW5ITVJ?
SW954 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL3TWM2OD15LkKwNFY5KM7:TR?= MX3TRW5ITVJ?
NCI-H441 MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTdwM{SwOlUh|ryP M3HjV3NCVkeHUh?=
SK-MEL-2 MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTdwNEizO|Mh|ryP Mnn0V2FPT0WU
KARPAS-45 NFLYc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTdwNkW5Nlkh|ryP M2DDZnNCVkeHUh?=
CAL-54 NF\1dYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTTbJdMUUN3ME23MlgzQTd5IN88US=> NYHNV4RJW0GQR1XS
KYSE-180 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\UTWM2OD15Lki4PVQyKM7:TR?= MnvkV2FPT0WU
NCI-H187 M{i2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjQWXpRUUN3ME23Mlk2QTR5IN88US=> MonnV2FPT0WU
RT-112 NFrrdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfyTWM2OD16LkC5Olc4KM7:TR?= MnjzV2FPT0WU
NCI-H1437 NXfrSIhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2zRnBKSzVyPUiuNFk4QTVizszN NH:4Ro5USU6JRWK=
SNU-449 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRThwMkiyO|Ih|ryP M3:wOnNCVkeHUh?=
HCC1187 NH;i[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrRbXBxUUN3ME24MlI6OzlzIN88US=> Mm\sV2FPT0WU
NCI-H2030 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRThwM{e3NVQh|ryP Ml3NV2FPT0WU
HuO-3N1 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHhTWM2OD16LkO3PFQ1KM7:TR?= MVzTRW5ITVJ?
COLO-792 NGrIeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvLbI1rUUN3ME24MlQyPTJ5IN88US=> NX;hUWk3W0GQR1XS
MIA-PaCa-2 M4LzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXT[pIyUUN3ME24Mlg2PTB6IN88US=> M3XVSXNCVkeHUh?=
SK-N-FI MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTlwMESyOUDPxE1? NWnpd4g{W0GQR1XS
MMAC-SF NE\LTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j3WWlEPTB;OT6wPVc2OSEQvF2= NH;DXlRUSU6JRWK=
NCI-H28 NH71dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DkTGlEPTB;OT6xNFQ3QSEQvF2= M{TJc3NCVkeHUh?=
ETK-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nPdmlEPTB;OT6yPVk4PCEQvF2= NF\ER3FUSU6JRWK=
NCI-H1993 NY\1d3NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLRUXBKSzVyPUmuOFQzPjFizszN M3\4d3NCVkeHUh?=
no-11 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGy[HJKSzVyPUmuOFcyOiEQvF2= MUjTRW5ITVJ?
ChaGo-K-1 NVr3SI9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nJemlEPTB;OT61NVU5OyEQvF2= M1f3cXNCVkeHUh?=
NCCIT M3fhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3Pb4xKSzVyPUmuOVMyPjlizszN NVLJb|FbW0GQR1XS
SAS NYm2dHI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O0R2lEPTB;MUCuNlQ5KM7:TR?= NEfy[IJUSU6JRWK=
A673 M4TPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLhTWM2OD1zMD6zO|A1KM7:TR?= MWjTRW5ITVJ?
NCI-H1522 NUX3[FB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFyLkO3NFch|ryP MVfTRW5ITVJ?
NCI-H810 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq2T4hKSzVyPUGwMlM6ODdizszN MlLwV2FPT0WU
IST-MES1 NEnETnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MliwTWM2OD1zMD60OVY1KM7:TR?= M33zTHNCVkeHUh?=
GR-ST NEnYN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC2VXZKSzVyPUGwMlUxOjRizszN NYmwN4NWW0GQR1XS
SUP-T1 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XoXWlEPTB;MUCuO|MyPyEQvF2= MUHTRW5ITVJ?
NB5 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly3TWM2OD1zMD65NFIzKM7:TR?= NIrONIpUSU6JRWK=
MZ1-PC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPodJpMUUN3ME2xNE46PTdzIN88US=> NF\PSFZUSU6JRWK=
SK-CO-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETaOYZKSzVyPUGwMlk6OzFizszN MXXTRW5ITVJ?
Capan-2 NYrGS4M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjpSm5KSzVyPUGxMlMyQThizszN NXz1doptW0GQR1XS
697 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFzLk[3OVch|ryP M2m4THNCVkeHUh?=
REH NInJ[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLKTWM2OD1zMT63OFUyKM7:TR?= NWLHeplXW0GQR1XS
GI-1 NUTveIk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP5TWM2OD1zMT64OlE2KM7:TR?= M1u2XnNCVkeHUh?=
BB65-RCC NH71W3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfzXFhKSzVyPUGyMlA6OTZizszN NESxTpNUSU6JRWK=
NCI-H1651 NXy3[VVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF{LkK0O|gh|ryP MkPVV2FPT0WU
NCI-H1618 MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF{LkO5O|Yh|ryP MmPEV2FPT0WU
NCI-H2081 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlziTWM2OD1zMj62NVQyKM7:TR?= M13VRnNCVkeHUh?=
GCIY MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF{LkeyNVMh|ryP NUD4WG1xW0GQR1XS
NY M4DjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTUTWM2OD1zMz6wOlQ{KM7:TR?= NIDuZVFUSU6JRWK=
PANC-03-27 NHL4SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;Qd|VKSzVyPUGzMlA5ODdizszN NYDtepZ4W0GQR1XS
BHY MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr5bIFKSzVyPUGzMlIyOjFizszN M3LVfXNCVkeHUh?=
SK-OV-3 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;oSZNjUUN3ME2xN{4{PzZ|IN88US=> NXGwdWdVW0GQR1XS
5637 NEPW[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq5fYxXUUN3ME2xN{44PzV7IN88US=> M3HydXNCVkeHUh?=
LC-1F NHrueoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37zOGlEPTB;MUSuNFM2PiEQvF2= NYHqb2FwW0GQR1XS
SNB75 NWj3bmhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInWOWZKSzVyPUG0MlA{QDNizszN M3XucHNCVkeHUh?=
CHP-212 NH\wXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojTTWM2OD1zND6wOFY1KM7:TR?= MWDTRW5ITVJ?
HT-1376 M4\qcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDTTWM2OD1zND6xNVI3KM7:TR?= MULTRW5ITVJ?
MONO-MAC-6 NULrc5NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF2LkG1NFIh|ryP NUDMWI9OW0GQR1XS
CA46 NHSwNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF2LkG4Nlch|ryP MXXTRW5ITVJ?
SCC-15 NEDqdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7JTWM2OD1zND61OVg{KM7:TR?= MoHtV2FPT0WU
ATN-1 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7OZpNKSzVyPUG0MlY3OjdizszN MYDTRW5ITVJ?
NCI-H2405 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF2LkixOVch|ryP M{PZVHNCVkeHUh?=
NCI-H716 NYqyOVNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLtTWM2OD1zND64OFk{KM7:TR?= NYLVN4R6W0GQR1XS
SW620 M{ntR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF2LkmwNVQh|ryP M{nsXXNCVkeHUh?=
NCI-H226 M1j1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PL[mlEPTB;MUSuPVA5PSEQvF2= NVHNT5hqW0GQR1XS
SW962 NGfQTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H5dWlEPTB;MUSuPVQ{OiEQvF2= MW\TRW5ITVJ?
KYSE-150 NYXwR2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTrV3hKSzVyPUG0Mlk2PSEQvF2= NV\aeWptW0GQR1XS
OCUB-M NFX2O4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfWfGVKSzVyPUG0Mlk5QDNizszN M4HDXnNCVkeHUh?=
ES7 NWTwN5l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Xd2lEPTB;MUWuNFk5PCEQvF2= M{fuWXNCVkeHUh?=
SW1463 M2PV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XFdGlEPTB;MUWuOFIzOyEQvF2= M4HhTHNCVkeHUh?=
CAKI-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\iTWM2OD1zNT61N|Q3KM7:TR?= MkfmV2FPT0WU
MKN28 M1G4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrrflZKSzVyPUG1MlU1PzlizszN NHXnbHVUSU6JRWK=
SW13 NWmyXWp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fHcmlEPTB;MUWuOlE5KM7:TR?= MnLPV2FPT0WU
A3-KAW NI\JRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L4bWlEPTB;MUWuPVY6PyEQvF2= M3T2XHNCVkeHUh?=
LU-65 NEfOUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;LVoVKSzVyPUG1Mlk4PjhizszN Ml7oV2FPT0WU
Calu-1 M1zLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzCTINKSzVyPUG2MlA{PjhizszN MlrmV2FPT0WU
ST486 NIfJN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPXTZFKSzVyPUG2MlA1OzFizszN MXPTRW5ITVJ?
BB30-HNC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;3TWM2OD1zNj6xNlQ3KM7:TR?= NGr0VVRUSU6JRWK=
EGI-1 M1e1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf5dXRFUUN3ME2xOk41PDZizszN MVzTRW5ITVJ?
SH-4 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXJNYpYUUN3ME2xOk41PzNzIN88US=> MlvnV2FPT0WU
MN-60 M2HZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;oPWVKSzVyPUG3MlIzQTdizszN NV\qZYVsW0GQR1XS
MPP-89 M2LqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTjTWM2OD1zNz6yOFU6KM7:TR?= MV7TRW5ITVJ?
A2780 NXnETFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\GNHF7UUN3ME2xO{41OTN7IN88US=> NX3KVZI{W0GQR1XS
Daoy M1K0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HEZWlEPTB;MUeuOFY6PSEQvF2= MXvTRW5ITVJ?
NCI-H2126 NInobWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XaPGlEPTB;MUeuOFc4OSEQvF2= MY\TRW5ITVJ?
NCI-H1563 NIXrU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF5LkS5NVch|ryP M3j6[nNCVkeHUh?=
8-MG-BA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF5Lk[2OFgh|ryP MmjsV2FPT0WU
786-0 NUC2WodZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK2ZpNKSzVyPUG3Mlg{PTNizszN M4jQVXNCVkeHUh?=
AM-38 NY\6bIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;s[ZJKSzVyPUG3Mlk{ODZizszN NWrqNoRwW0GQR1XS
COLO-824 NYPvT|N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTlTHR4UUN3ME2xPE41PDN4IN88US=> NFu0fmVUSU6JRWK=
SK-MEL-30 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTxN|FMUUN3ME2xPE42ODh{IN88US=> MYfTRW5ITVJ?
CESS NXyySIVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nKXGlEPTB;MUiuO|YxQSEQvF2= MWHTRW5ITVJ?
BL-70 M4DoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vEcGlEPTB;MUiuPFE2PiEQvF2= Mo\4V2FPT0WU
NCI-H2170 M1fUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O3S2lEPTB;MUiuPVE4QSEQvF2= M3;IN3NCVkeHUh?=
HT-3 NUfJXpJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrlXnRKSzVyPUG4Mlk5OyEQvF2= M2K4bXNCVkeHUh?=
BOKU Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF7LkCzPFEh|ryP MlfsV2FPT0WU
HPAF-II M2jmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Sz[GlEPTB;MUmuN|AyPSEQvF2= NGqxRZBUSU6JRWK=
KGN M{XPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL4fGpEUUN3ME2xPU41PzZ3IN88US=> NGfxXJNUSU6JRWK=
MC-CAR MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF7Lk[zNVMh|ryP NGrndItUSU6JRWK=
BHT-101 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrqWmtTUUN3ME2xPU44PzdizszN NH7pTGlUSU6JRWK=
SW1783 NXmyU48yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLrOZRyUUN3ME2xPU44QDB4IN88US=> MYnTRW5ITVJ?
KP-N-YN NIDibWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTVTWM2OD1{MD6wNlYzKM7:TR?= NHPuTnFUSU6JRWK=
LU-165 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LLUGlEPTB;MkCuOVU4OSEQvF2= MW\TRW5ITVJ?
GOTO M2jPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELvcW9KSzVyPUKwMlY1PTFizszN MVXTRW5ITVJ?
EFM-19 NFX1WYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnYNmlKSzVyPUKxMlA4OTZizszN NVPhblB4W0GQR1XS
CTV-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJzLkGwOVQh|ryP NFH4VHdUSU6JRWK=
HEL M{\kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL2[I5nUUN3ME2yNU41OjF4IN88US=> MkC2V2FPT0WU
SNU-C2B NWjpN3NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7TUlVKSzVyPUKxMlQzPiEQvF2= M{DWenNCVkeHUh?=
ECC4 NInaW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnCTWM2OD1{MT63NFch|ryP M3HkVnNCVkeHUh?=
NEC8 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH1UINKSzVyPUKxMlg{PjhizszN MV3TRW5ITVJ?
KMOE-2 NV;wXpg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LIfGlEPTB;MkGuPFkzOSEQvF2= NVfrPGhPW0GQR1XS
NCI-H524 NEi3cFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz3TWM2OD1{Mj6wPFA5KM7:TR?= MVrTRW5ITVJ?
WSU-NHL NVjWS5doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vPN2lEPTB;MkKuNVU4PyEQvF2= NFXTbnNUSU6JRWK=
SF126 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1yycmlEPTB;MkKuNlQ3QSEQvF2= NVH6eVRUW0GQR1XS
HOP-92 M4nvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ{LkOxOlch|ryP NFH0V4VUSU6JRWK=
CTB-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q0OmlEPTB;MkKuOFY4PyEQvF2= NGHRfZhUSU6JRWK=
KYSE-270 M33ZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TMVWlEPTB;MkKuPVM2PyEQvF2= Mmn6V2FPT0WU
SK-MEL-24 NXTZW3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJ|LkG4O{DPxE1? NVTHRnFXW0GQR1XS
Calu-3 NH6xZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ|LkKxNlgh|ryP M1vLSXNCVkeHUh?=
GAMG MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi2VWJKSzVyPUKzMlI{PjdizszN NEHIemJUSU6JRWK=
SW1573 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W4e2lEPTB;MkOuO|QyPSEQvF2= M1;6ZXNCVkeHUh?=
MHH-NB-11 NUPGV4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2naWWlEPTB;MkSuNFE6PCEQvF2= MnG4V2FPT0WU
TK10 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXqWFFKSzVyPUK0MlUxOTNizszN MVHTRW5ITVJ?
LB373-MEL-D NXTqVIdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHzTWM2OD1{ND62NFY1KM7:TR?= NUi2SGRxW0GQR1XS
KALS-1 M3PwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDReFVLUUN3ME2yOE44OzJ5IN88US=> M1fDcHNCVkeHUh?=
HUTU-80 NX3rRVBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\FRWlEPTB;MkWuPFA{OiEQvF2= NHT0fnBUSU6JRWK=
HuP-T3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjYZ|U2UUN3ME2yOk4yPjd2IN88US=> Mof2V2FPT0WU
OE19 NFXqSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXUSHBKSzVyPUK2MlIyPTNizszN MnyzV2FPT0WU
J82 NFi1bYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfpZmhyUUN3ME2yOk4zPDdzIN88US=> NUPmbW5CW0GQR1XS
DU-4475 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\NTWM2OD1{Nj6zPFE6KM7:TR?= MX;TRW5ITVJ?
DMS-53 NFryfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zWVWlEPTB;Mk[uOVE{QCEQvF2= NYjJVIdZW0GQR1XS
COLO-741 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml25TWM2OD1{Nj64N|Q1KM7:TR?= NFj4OZdUSU6JRWK=
SW48 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PUPGlEPTB;Mk[uPFgzKM7:TR?= M3PpTXNCVkeHUh?=
IGR-1 M1zVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2wTWM2OD1{Nj65N|M1KM7:TR?= NUf4fHA{W0GQR1XS
639-V NHjwbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrRcoNXUUN3ME2yO{4xOjR3IN88US=> MlfQV2FPT0WU
LK-2 NW\Tc4RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTxTWM2OD1{Nz60NVQyKM7:TR?= M1\LOXNCVkeHUh?=
NCI-H2347 NEPsNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\lemlEPTB;MkeuPVY6QSEQvF2= MnzIV2FPT0WU
NCI-H2228 NV7PSWlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomwTWM2OD1{OD6wPVA2KM7:TR?= MVjTRW5ITVJ?
LS-123 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq0TWM2OD1{OD6xNlYzKM7:TR?= MUfTRW5ITVJ?
U031 NY\NbHFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TrRWlEPTB;MkiuNlUzKM7:TR?= MX3TRW5ITVJ?
NCI-H1792 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL1OWtKSzVyPUK4MlQ4OjFizszN MUPTRW5ITVJ?
NCI-H2087 NYK2eJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqweFVKSzVyPUK4Mlc2PTJizszN MlfJV2FPT0WU
NCI-H2342 MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW4N4J{UUN3ME2yPU42OjB6IN88US=> MVPTRW5ITVJ?
SW626 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ7Lke1OkDPxE1? MXHTRW5ITVJ?
LB2518-MEL MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlntTWM2OD1{OT64NVUh|ryP MUnTRW5ITVJ?
RXF393 M1XYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNyLkC5OVIh|ryP NEP1TolUSU6JRWK=
LC4-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\wRppKSzVyPUOwMlMxQTJizszN Mlr0V2FPT0WU
NCI-H1694 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPLTWM2OD1|MD62OlI1KM7:TR?= NHThfWtUSU6JRWK=
K5 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNyLkm3NFIh|ryP M2rkTnNCVkeHUh?=
HDLM-2 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDoTWM2OD1|MD65O|I2KM7:TR?= MUnTRW5ITVJ?
BCPAP M1P3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\EW4RKSzVyPUOxMlg{PzlizszN M4PUUnNCVkeHUh?=
BC-3 NHX5cldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[1TWM2OD1|Mj6xOFA{KM7:TR?= NEjUeXFUSU6JRWK=
LB996-RCC M4G4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\FWFNKSzVyPUOyMlI{PThizszN M3LyVXNCVkeHUh?=
NCI-H2009 M1u1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[2OGZKSzVyPUOyMlQ6QDFizszN NEfhelBUSU6JRWK=
HTC-C3 NYHaNJZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN|Lke1NVkh|ryP NF[4eW1USU6JRWK=
LAMA-84 NHrsdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zuNmlEPTB;M{SuOFQxPyEQvF2= MlvtV2FPT0WU
CCRF-CEM M3fiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH5UHdKSzVyPUO0MlU4OTVizszN MUjTRW5ITVJ?
AN3-CA MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13JU2lEPTB;M{WuNFU3QCEQvF2= NWPL[ZdxW0GQR1XS
NCI-H1734 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnYTYxKSzVyPUO1MlI2PjFizszN NEXncnhUSU6JRWK=
Ca-Ski NIrC[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTN3LkSxNFEh|ryP MUPTRW5ITVJ?
U-266 NGSxNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTN3Lk[xNVQh|ryP MVrTRW5ITVJ?
SBC-5 NWHmV3FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTN3Lke3PFEh|ryP NEPuVlJUSU6JRWK=
GT3TKB MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnsUZVKSzVyPUO3MlEyPSEQvF2= M{T2VnNCVkeHUh?=
MDA-MB-175-VII NEf5O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCTWM2OD1|Nz6yNlQ5KM7:TR?= MnPWV2FPT0WU
PFSK-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\UcmhKSzVyPUO3MlI1OzVizszN NXnhOGhDW0GQR1XS
IMR-5 NVn4W4RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HIXWlEPTB;M{euNlQ5PyEQvF2= MVfTRW5ITVJ?
Daudi MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjCfZo5UUN3ME2zO{4{PTl5IN88US=> MmXEV2FPT0WU
A498 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHrem5XUUN3ME2zO{44OjF6IN88US=> NIXxdFNUSU6JRWK=
SCC-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ezZmlEPTB;M{euO|g1OyEQvF2= MkLOV2FPT0WU
COLO-680N NEmyN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PNfGlEPTB;M{iuNlg5PSEQvF2= MXrTRW5ITVJ?
SK-MES-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTN6LkOyNVUh|ryP NHzHenJUSU6JRWK=
SR NFP3[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN6LkW0PVUh|ryP MYnTRW5ITVJ?
LNCaP-Clone-FGC NIWyW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW3ZVk3UUN3ME2zPE42PjN5IN88US=> NUPpcIVOW0GQR1XS
SK-HEP-1 M1roT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnQdGxKSzVyPUO4Mlc5OjJizszN MYDTRW5ITVJ?
BPH-1 NFPhTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTmW4VEUUN3ME2zPE45OzJ7IN88US=> MoDuV2FPT0WU
NCI-H1755 NFPaT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rXWmlEPTB;M{muOVgyPyEQvF2= NV;wRYxUW0GQR1XS
LXF-289 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16yOGlEPTB;M{muPFA5PCEQvF2= M3X1UHNCVkeHUh?=
SW1088 NVH0cVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\iTWM2OD12MD6yNVA4KM7:TR?= M{jlcXNCVkeHUh?=
MOLT-4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn2fnJpUUN3ME20NE4zQTBzIN88US=> NWLDSW11W0GQR1XS
AsPC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nQPWlEPTB;NECuOFU5OyEQvF2= M{iwOnNCVkeHUh?=
HOP-62 NHnoTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRyLk[1Olgh|ryP MmXwV2FPT0WU
A172 MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfWcph{UUN3ME20NE45PTFzIN88US=> M13ZXnNCVkeHUh?=
SN12C M1fUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\PR3JKSzVyPUSwMlk{QDVizszN NH\2UYVUSU6JRWK=
MDA-MB-231 M1LEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof5TWM2OD12MD65PFk5KM7:TR?= MVTTRW5ITVJ?
RPMI-2650 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRzLkG1PVMh|ryP NETESmtUSU6JRWK=
KYSE-140 NEOzeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTMTWM2OD12MT64NVI{KM7:TR?= MULTRW5ITVJ?
KINGS-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13UOmlEPTB;NEKuOFY6PyEQvF2= NFizeHNUSU6JRWK=
HSC-3 M{LWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf2XoRKSzVyPUSyMlY3PjFizszN M4fzS3NCVkeHUh?=
PC-14 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvkV5k6UUN3ME20N{4yQDh{IN88US=> MXXTRW5ITVJ?
COR-L105 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHaTWM2OD12Mz62OVAzKM7:TR?= M4\HSnNCVkeHUh?=
BE-13 NE\ZUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XaPWlEPTB;NESuNlM4OSEQvF2= Mk[5V2FPT0WU
NCI-H661 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXoSoJVUUN3ME20OE4zQTV6IN88US=> NUDyNIk2W0GQR1XS
IST-MEL1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTR2LkO1PVkh|ryP M4DW[HNCVkeHUh?=
HCC1806 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL6TWM2OD12ND61PFc{KM7:TR?= NH\vZ3RUSU6JRWK=
COLO-800 NFHjUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTR2Lki0OVMh|ryP NHPUdm5USU6JRWK=
IST-SL2 NHziUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTDPWxKSzVyPUS1MlEzPDdizszN NEmxV2hUSU6JRWK=
8305C NF\FSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq2TWM2OD12NT6zNFkh|ryP NUnXeoxiW0GQR1XS
UACC-62 M3jlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:yXXZ2UUN3ME20Ok4zQDd3IN88US=> M164XHNCVkeHUh?=
COR-L23 MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTR5LkG5PUDPxE1? M4PDTXNCVkeHUh?=
EFE-184 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LHVmlEPTB;NEeuN|g5KM7:TR?= MXPTRW5ITVJ?
DMS-114 NVvHPXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qzWmlEPTB;NEeuOFE1QSEQvF2= Mm\lV2FPT0WU
KYSE-520 M3\USWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTR6LkWzNVUh|ryP NUTI[JRZW0GQR1XS
SNG-M NYDl[FlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33ISGlEPTB;NEmuOFM1KM7:TR?= NHzOfpBUSU6JRWK=
A2058 NE\1PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUCwOFJqUUN3ME20PU41QDh3IN88US=> MmLSV2FPT0WU

多くの細胞株試験データを見る場合、クリックしてください

体内試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
細胞試験: [1]
+ 展開
  • 細胞株: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • 濃度: 0.02-0.8 μM
  • 反応時間: 3 days
  • 実験の流れ: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • 製剤: 25 mM tartaric acid
  • 投薬量: 25 mg / kg and 75 mg / kg
  • 投与方法: Orally administrated at once-daily oral dose for 14 days
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R信号経路図

IGF-1R Inhibitors with Unique Features

相関IGF-1R製品

Tags: Linsitinib (OSI-906)を買う | Linsitinib (OSI-906) ic50 | Linsitinib (OSI-906)供給者 | Linsitinib (OSI-906)を購入する | Linsitinib (OSI-906)費用 | Linsitinib (OSI-906)生産者 | オーダーLinsitinib (OSI-906) | Linsitinib (OSI-906)化学構造 | Linsitinib (OSI-906)分子量 | Linsitinib (OSI-906)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID